Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer

Huang, Lei; Chen, Shengxi; Huang, Yan; Luo, Wanjun; Jiang, Haihe; Hu, Qinghua; Zhang, Peng-Fei; Yi, Hong

doi:10.1016/j.lungcan.2006.06.011

Cited by 75 publications

(66 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through our method, we successfully identified proteins that are putative or currently used as biomarkers of lung cancer, including CEA (27,28), pro-GRP (29,31), SCC antigen (47,48), tumor M2-PK (49), NCAM (35)(36)(37), chromogranin A (29), and chromogranin B (30). In addition, we identified putative markers previously reported in lung-related proteomics studies such as member C1 of aldo-keto reductase family 1 identified by Huang et al (25) as dihydrodiol dehydrogenase and matrix metallopeptidase 1 found to be overexpressed in lung cancer patients and especially in late stage (18). Furthermore, 129 of 291 extracellular and 168 of 415 membranous proteins identified in this study were found in the plasma proteome.…”

Section: Discussionmentioning

confidence: 99%

“…Then, we performed literature searches to ensure that these proteins have not been examined as serological markers for lung cancer and showed biological connections with lung or other cancers. We also compared selected proteins with the proteomes of lung-related diseases (lung cancer (18,25,26) and pleural effusion (11)) or the proteome of a lung-related biological fluid (induced sputum (9, 10)) and serum (Plasma Proteome Database). Finally, potential candidates that had commercially available antibodies or immunoassays were selected.…”

Section: Discussionmentioning

confidence: 99%

“…Using one-dimensional PAGE and nano-ESI-MS/MS, they identified 231 proteins of which 161 (70%) were also found in our proteomics study. Huang et al (25) analyzed secreted proteins in the CM of an NSCLC cell line (A549) by 2D PAGE and MALDI-TOF MS. Fourteen human proteins were identified of which 11 (79%) were also found by us, including ␣-enolase, peroxiredoxin 1, galectin 1, ubiquitin carboxyl-terminal hydrolase (PGP9.5), and dihydrodiol dehydrogenase. In addition, comparative proteomics analysis of the two NSCLC cell lines with different metastatic potential was carried out using 2DE followed by MALDI-TOF MS and MS/MS analysis.…”

Section: Classification Of Proteins Identified By Ms By Cellularmentioning

confidence: 99%

See 2 more Smart Citations

Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines

Planque

Kulasingam

Smith

et al. 2009

Molecular & Cellular Proteomics

133

107

View full text Add to dashboard Cite

Detection of lung cancer at an early stage is necessary for successful therapy and improved survival rates. We performed a bottom-up proteomics analysis using a twodimensional LC-MS/MS strategy on the conditioned media of four lung cancer cell lines of different histological backgrounds (non-small cell lung cancer: H23 (adenocarcinoma), H520 (squamous cell carcinoma), and H460 (large cell carcinoma); small cell lung cancer: H1688) to identify secreted or membrane-bound proteins that could be useful as novel lung cancer biomarkers. Proteomics analysis of the four conditioned media allowed identification of 1,830 different proteins (965, 871, 726, and 847 from H1688, H23, H460, and H520, respectively). All proteins were assigned a subcellular localization, and 38% were classified as extracellular or membrane-bound. We successfully identified the internal control proteins (also detected by ELISA), kallikrein-related peptidases 14 and 11, and IGFBP2. We also identified known or putative lung cancer tumor markers such as squamous cell carcinoma antigen, carcinoembryonic antigen, chromogranin A, creatine kinase BB, progastrin-releasing peptide, neural cell adhesion molecule, and tumor M2-PK. To select the most promising candidates for validation, we performed tissue specificity assays, functional classifications, literature searches for association to cancer, and a comparison of our proteome with the proteome of lung-related diseases and serum. Five novel lung cancer candidates, ADAM-17, osteoprotegerin, pentraxin 3, follistatin, and tumor necrosis factor receptor superfamily member 1A were preliminarily validated in the serum of patients with lung cancer and healthy controls. Our results demonstrate the utility of this cell culture proteomics approach to identify secreted and shed proteins that are potentially useful as serologi-

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Classification Of Proteins Identified By Ms By Cellularmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines

Planque

Kulasingam

Smith

et al. 2009

Molecular & Cellular Proteomics

133

107

View full text Add to dashboard Cite

show abstract

“…The potencies of serum amyloid A [145,146], haptoglobinalpha [147] and a fragment of apolipoprotein A-1 [148] as lung cancer biomarkers are mentioned in some studies but need further clinical validation. Plasma kallikrein B1 (KLKB1) fragments have potential to be a biomarker for diagnosis of lung adenocarcinoma [149].…”

Section: Potential Of Lung Cancer Protein Biomarkersmentioning

confidence: 99%

Serum-based protein biomarkers for detection of lung cancer

2014

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers in terms of both incidence and mortality.The major reasons for the increasing number of deaths from lung cancer are late detection and lack of effective therapies. To improve our understanding of lung cancer biology, there is urgent need for blood-based, non-invasive molecular tests to assist in its detection in a cost-effective manner at an early stage when curative interventions are still possible. Recent advances in proteomic technology have provided extensive, high throughput analytical tools for identification, characterization and functional studies of proteomes. Changes in protein expression patterns in response to stimuli can serve as indicators or biomarkers of biological and pathological processes as well as physiological and pharmacological responses to drug treatment, thus aiding in early diagnosis and prognosis of disease. However, only a few biomarkers have been approved by the FDA to date for screening and diagnostic purposes. This review provides a brief overview of currently available proteomic techniques, their applications and limitations and the current state of knowledge about important serum biomarkers in lung cancer and their potential value as prognostic and diagnostic tools.

show abstract

“…In many cases, the definite diagnosis of lung cancer is based on pathological examination of the biopsy, an invasive surgical procedure that is not suitable for all kinds of lung cancer (Adams et al, 2012). For these reasons, progress on the prevention, diagnosis, and treatment of lung cancer may largely depend on the discovery of specific tumor markers that can distinguish and characterize lung cancer of different subtypes and stages (Huang et al, 2006).…”

Section: 2273 Proteomic Profiling Of Serum From Stage I Lung Squamoumentioning

confidence: 99%

Proteomic Profiling of Serum from Stage I Lung Squamous Cell Carcinoma Patients

Wu²,

He³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objectives: This study employed proteomic profiling to identify specific tumor markers that might improve early diagnosis of lung squamous cell carcinoma. Methods: Serum samples were isolated from 30 patients with stage I lung squamous cell carcinoma and 30 age-and gender-matched healthy controls, and proteomic profiles were obtained by matrix-assisted laser desorption ionization time of flight mass spectrometry. Results: Three highly expressed potential tumor markers were identified in the sera of stage I lung squamous cell carcinoma patients, with molecular weights of 3261.69, 3192.07, and 2556.92 Da. One protein peak with molecular weight 3261.69 Da was chosen as the candidate biomarker and identified as a fibrinogen alpha chain through a search of the IPI, NCBI or SWISS-PROT protein databases. Conclusion: As a potential tumor biomarker, fibrinogen alpha chain may be applicable for the early diagnosis and prognosis of lung squamous cell carcinoma patients.

show abstract

Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer

Cited by 75 publications

References 21 publications

Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines

Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines

Serum-based protein biomarkers for detection of lung cancer

Proteomic Profiling of Serum from Stage I Lung Squamous Cell Carcinoma Patients

Contact Info

Product

Resources

About